daunorubicin has been researched along with panobinostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, SD; Buck, SA; Caldwell, JT; Chen, W; Drenberg, C; Edwards, H; Ge, Y; Inaba, H; Taub, JW; Xie, C; Xu, X | 1 |
| Edwards, H; Ge, Y; Taub, JW; Wang, G; Xie, C; Zhao, J | 1 |
1 trial(s) available for daunorubicin and panobinostat
| Article | Year |
|---|---|
Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; BRCA1 Protein; Checkpoint Kinase 1; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Agonism; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Leukemic; Heterografts; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; M Phase Cell Cycle Checkpoints; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Panobinostat; Protein Kinases; Rad51 Recombinase; U937 Cells | 2013 |
1 other study(ies) available for daunorubicin and panobinostat
| Article | Year |
|---|---|
Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; BRCA1 Protein; Cell Cycle; Checkpoint Kinase 1; Cytarabine; Daunorubicin; DNA Damage; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Panobinostat; Rad51 Recombinase; RNA Interference; Signal Transduction; THP-1 Cells; Transfection | 2017 |